Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Page 4 of 8« First...23456...Last »

Europe approves GSK’s new triple lung drug

The European Commission approved GlaxoSmithKline’s three-in-one inhaler Trelegy Ellipta for chronic lung disease.

Read More »

TokBox reveals “Live Video Maturity Study” results

The live video, real-time communications company (RTC) TokBox announced the results of its inaugural “Live Video Maturity Study.”

Read More »

Amgen’s Repatha Reduces Cardiovascular Events in Patients with a History of Heart Attacks

Amgen’s PSCK9 inhibitor Repatha continues to impress as a treatment for patients with peripheral artery disease (PAD) and a history of heart attacks. New data shows Repatha hit its primary endpoints and significantly reduced first-time cardiovascular events by 27 percent in PAD patients.

Read More »

Sangamo Scores Bragging Rights for First-in-Human Gene Editing Trial

Barely a week after announcing it was moving into a new corporate headquarters, Sangamo Therapeutics announced that the company has dosed the first patient in its Phase I/II gene therapy trial.

Read More »

Genentech Dumps Another $650 Million in New Haven Biotech Arvinas

New Haven, Conn.-based Arvinas expanded an ongoing licensing deal with Genentech. The agreement is to develop new drugs using Arvinas’ PROTAC technology. The original deal was inked in October 2015.

Read More »

FDA clears nerve stimulator for opioid withdrawal symptoms

The FDA approved an electrical nerve stimulator designed to reduce the symptoms of opioid withdrawal.

Read More »

Acorda reports five deaths in Parkinson’s trial

Acorda Therapeutics Inc. said five people died in clinical trials for the company’s Parkinson’s disease drug, the latest in a series of setbacks for the drugmaker.

Read More »

Maximizing Disease and Product Education Efforts in a Digital World

A combination of regulatory conditions, shifts in physician workplace demographics, and an increased reliance of highly specialized sales personnel has steadily eroded the traditional sales reps’ responsibilities and ability to manage the HCP practice relationship as a true SPOC.

Read More »

Shanghai Pharma buys U.S. Cardinal Health’s China business for $557 million

Shanghai Pharmaceuticals Holding Co. agreed to buy Cardinal Health Inc.’s China drug distribution business for $557 million, winning a highly competitive auction in a move that will greatly expand its presence nationwide.

Read More »

FDA approves AstraZeneca severe asthma drug

AstraZeneca achieved another milestone in rebuilding its drug portfolio with U.S. approval of Fasenra for severe asthma.

Read More »

Novartis Showcases 4 Potential Blockbusters in Its Late-Stage Pipeline

Swiss-based Novartis is showcasing four key drugs from the company’s late stage pipeline at an R&D and investor event in England.

Read More »

Mylan Chops Another 200 to 300 Jobs

Mylan reportedly let go between 200 and 300 people from its West Virginia operations.

Read More »

Loxo Oncology, Bayer Strike Cancer Deal

Loxo Oncology struck a deal with Bayer AG to develop and commercialize two cancer therapies worth up to $1.55 billion.

Read More »

FDA warns against using kratom for opioid addiction

The U.S. Food and Drug Administration warned about the usage of kratom, citing reports of 36 deaths, and said there is no reliable evidence to support its use to treat opioid withdrawal symptoms.

Read More »

Janssen drops U.S. lawsuit against Samsung Bioepis’ Remicade copy

A unit of healthcare conglomerate Johnson & Johnson dropped a lawsuit it filed to block a copy of the company’s rheumatoid arthritis drug Remicade produced by South Korea’s Samsung Bioepis Co. Ltd. from being sold in the United States.

Read More »

Sandoz says new clinical data support two biosimilars

Novartis’ generics division Sandoz said new immunology data from four clinical studies supported its proposed biosimilars adalimumab for treating psoriasis and cancer drug rituximab.

Read More »

U.S. approves digital pill that tracks when patients take it

U.S. regulators approved the first digital pill with an embedded sensor to track if patients are taking their medication properly, marking a significant step forward in the convergence of healthcare and technology.

Read More »

Zymeworks, Janssen Biotech Ink R&D Deal

Shares of Zymeworks shot up more than 33 percent after the company announced a licensing deal with Janssen Biotech to develop six bispecific antibodies.

Read More »

Argos Reports Positive Kidney Cancer Data

Argos Therapeutics announced positive interim data for the company’s kidney cancer drug Rocapuldencel-T from a Phase III clinical trial.

Read More »

Novartis’ canakinumab reduced cardiovascular risk by 25 percent in subgroup of CANTOS Phase III trial participants

Novartis announced results from a new analysis of the Phase III CANTOS study presented by Dr. Paul Ridker at the American Heart Association (AHA) Scientific Sessions 2017 and published simultaneously in The Lancet.

Read More »

Page 4 of 8« First...23456...Last »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2018 Focus: Top 200 Meds, Year After Launch, VR/AR and more!


Ad Right Bottom